Publication | Closed Access

Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial

Egfrviii-expressing GlioblastomaNeuro-oncologyAct IvGliomaInternational Phase 3MedicineMetronomic TherapyPharmacologyPathologyHigh-grade GliomasCancer TreatmentOncologyRadiation Oncology